United States Pharmaceuticals

Royalty Pharma PLC (RPRX)

Track

Royalty Pharma PLC insiders executed 22 transactions totaling approximately $43.95 million in sales over the past 90 days. Key executives, including Christopher Hite and Marshall Urist, conducted these planned divestments. This activity follows a 10.4% stock price increase and a positive earnings report, with shares currently trading near their 52-week high.
Ticker: RPRX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Royalty Pharma PLC. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 1 Jul 2026
Value US$1,898,086.68 | Price 442.54 | Shares 33,396 (+3.6%)
Proposed sale 1 Jul 2026
Value US$4,096,885.68 | Price 146.73 | Shares 99,294
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-02 2026-07-01 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
33,396 +3.6%
442.54
US$1,898,087 		33,396 +3.6% 442.54 US$1,898,087
2026-07-01 2026-07-01 PrS Proposed sale
3.5
Urist Marshall

Officer

Officer
99,294
146.73
US$4,096,886 		99,294 146.73 US$4,096,886
2026-07-02 2026-06-30 PlS Planned sale
Hite Christopher

EVP & Chairman, Partnering

Officer
63,855 +25.3%
35.73
US$934,206 		63,855 +25.3% 35.73 US$934,206
2026-07-02 2026-06-30 PlS Planned sale
Hite Christopher

EVP & Chairman, Partnering

Officer
29,400 -42.0%
56.44
US$1,659,404 		29,400 -42.0% 56.44 US$1,659,404
2026-07-02 2026-06-30 PlS Planned sale
Hite Christopher

EVP & Chairman, Partnering

Officer
2,554 -0.6%
57.10
US$145,841 		2,554 -0.6% 57.10 US$145,841
2026-07-02 2026-06-30 PlS Planned sale
Hite Christopher

EVP & Chairman, Partnering

Officer
97,446 -17.4%
56.50
US$5,505,972 		97,446 -17.4% 56.50 US$5,505,972
2026-07-01 2026-06-30 PrS Proposed sale
SCH Investment Partners LLC

Officer

Officer
100,000
57.09
US$5,709,000 		100,000 57.09 US$5,709,000
2026-06-25 2026-06-24 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
9,098 -50.0%
55.18
US$502,067 		9,098 -50.0% 55.18 US$502,067
2026-06-24 2026-06-24 PrS Proposed sale
3.5
Urist Marshall

Officer

Officer
9,098
55.18
US$502,067 		9,098 55.18 US$502,067
2026-06-25 2026-06-23 PlS Planned sale
Hite Christopher

EVP & Chairman, Partnering

Officer
117,592 -17.4%
54.47
US$6,405,777 		117,592 -17.4% 54.47 US$6,405,777
2026-06-25 2026-06-23 PlS Planned sale
Hite Christopher

EVP & Chairman, Partnering

Officer
32,408 -4.6%
54.11
US$1,753,500 		32,408 -4.6% 54.11 US$1,753,500
2026-06-23 2026-06-23 PrS Proposed sale
Christopher Hite

Officer

Officer
30,000
55.35
US$1,660,500 		30,000 55.35 US$1,660,500
2026-06-23 2026-06-23 PrS Proposed sale
SCH Investment Partners LLC

Officer

Officer
150,000
54.45
US$8,166,766 		150,000 54.45 US$8,166,766
2026-05-28 2026-05-26 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
64,399 -100.0%
53.98
US$3,476,116 		64,399 -100.0% 53.98 US$3,476,116
2026-05-26 2026-05-26 PrS Proposed sale
3.8
Terrance Coyne

Officer

Officer
64,399
53.86
US$3,468,530 		64,399 53.86 US$3,468,530
2026-05-21 2026-05-20 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
13,684 -42.9%
52.75
US$721,838 		13,684 -42.9% 52.75 US$721,838
2026-05-20 2026-05-20 PrS Proposed sale
3.5
Urist Marshall

Officer

Officer
13,684
52.75
US$721,837 		13,684 52.75 US$721,837
2026-05-15 2026-05-14 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
13,684 -30.0%
53.06
US$726,137 		13,684 -30.0% 53.06 US$726,137
2026-05-15 2026-05-14 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
13,684 -30.0%
53.06
US$726,137 		13,684 -30.0% 53.06 US$726,137
2026-05-15 2026-05-14 PlS Planned sale
2.4
Norden Gregory
Non-Executive Director
3,045 -1.6%
53.00
US$161,385 		3,045 -1.6% 53.00 US$161,385
2026-05-14 2026-05-14 PrS Proposed sale
2.4
Norden Gregory

Officer

Officer
3,045
53.00
US$161,385 		3,045 53.00 US$161,385
2026-05-14 2026-05-14 PrS Proposed sale
3.5
Urist Marshall

Officer

Officer
13,684
53.06
US$726,138 		13,684 53.06 US$726,138
2026-04-30 2026-04-28 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
1,875 -4.5%
49.78
US$93,334 		1,875 -4.5% 49.78 US$93,334
2026-04-30 2026-04-28 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
32,916 -100.0%
49.78
US$1,638,506 		32,916 -100.0% 49.78 US$1,638,506
2026-04-28 2026-04-28 PrS Proposed sale
3.8
Terrance Coyne

Officer

Officer
34,791
49.54
US$1,723,546 		34,791 49.54 US$1,723,546
2026-04-02 2026-04-01 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
32,916 -50.0%
48.33
US$1,590,890 		32,916 -50.0% 48.33 US$1,590,890
2026-04-02 2026-04-01 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
32,916 -50.0%
48.33
US$1,590,890 		32,916 -50.0% 48.33 US$1,590,890
2026-04-02 2026-04-01 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
1,875 -4.3%
48.33
US$90,622 		1,875 -4.3% 48.33 US$90,622
2026-04-02 2026-04-01 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
1,875 -4.3%
48.33
US$90,622 		1,875 -4.3% 48.33 US$90,622
2026-04-01 2026-04-01 PrS Proposed sale
3.8
Terrance Coyne

Officer

Officer
34,791
48.49
US$1,687,016 		34,791 48.49 US$1,687,016
2026-03-25 2026-03-23 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
1,875 -4.1%
45.53
US$85,366 		1,875 -4.1% 45.53 US$85,366
2026-03-25 2026-03-23 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
32,916 -33.3%
45.53
US$1,498,623 		32,916 -33.3% 45.53 US$1,498,623
2026-03-23 2026-03-23 PrS Proposed sale
3.8
Terrance Coyne

Officer

Officer
34,791
45.61
US$1,586,818 		34,791 45.61 US$1,586,818
2026-03-19 2026-03-19 PrS Proposed sale
3.8
George Lloyd

Officer

Officer
36,518
45.53
US$1,662,665 		36,518 45.53 US$1,662,665
2026-03-18 2026-03-18 PrS Proposed sale
3.8
George Lloyd

Officer

Officer
100,462
45.79
US$4,600,155 		100,462 45.79 US$4,600,155
2026-03-04 2026-03-04 PrS Proposed sale
3.8
George Lloyd

Officer

Officer
136,980
47.43
US$6,496,961 		136,980 47.43 US$6,496,961
2026-03-04 2026-03-02 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
583 -1.3%
47.01
US$27,409 		583 -1.3% 47.01 US$27,409
2026-03-04 2026-03-02 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
1,292 -2.7%
46.67
US$60,304 		1,292 -2.7% 46.67 US$60,304
2026-03-04 2026-03-02 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
10,429 -9.6%
47.01
US$490,314 		10,429 -9.6% 47.01 US$490,314
2026-03-04 2026-03-02 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
22,487 -17.1%
46.67
US$1,049,507 		22,487 -17.1% 46.67 US$1,049,507
2026-03-02 2026-03-02 PrS Proposed sale
3.8
Terrance Coyne

Officer

Officer
34,791
47.47
US$1,651,529 		34,791 47.47 US$1,651,529
2026-02-25 2026-02-23 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
1,875 -3.8%
45.32
US$84,968 		1,875 -3.8% 45.32 US$84,968
2026-02-25 2026-02-23 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
32,916 -20.0%
45.32
US$1,491,638 		32,916 -20.0% 45.32 US$1,491,638
2026-02-23 2026-02-23 PrS Proposed sale
3.8
Terrance Coyne

Officer

Officer
34,791
45.47
US$1,581,947 		34,791 45.47 US$1,581,947
2026-02-04 2026-02-04 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
1,087 -4.5%
43.29
US$47,059 		1,087 -4.5% 43.29 US$47,059
2026-02-04 2026-02-04 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
19,076 -10.4%
43.29
US$825,853 		19,076 -10.4% 43.29 US$825,853
2026-02-04 2026-02-04 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
1,087 -4.5%
43.29
US$47,059 		1,087 -4.5% 43.29 US$47,059
2026-02-04 2026-02-04 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
19,076 -10.4%
43.29
US$825,853 		19,076 -10.4% 43.29 US$825,853
2026-02-04 2026-02-03 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
6,195 -20.5%
42.84
US$265,413 		6,195 -20.5% 42.84 US$265,413
2026-02-04 2026-02-03 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
108,759 -37.2%
42.84
US$4,659,584 		108,759 -37.2% 42.84 US$4,659,584
2026-02-04 2026-02-03 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
6,195 -20.5%
42.84
US$265,413 		6,195 -20.5% 42.84 US$265,413
2026-02-04 2026-02-03 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
108,759 -37.2%
42.84
US$4,659,584 		108,759 -37.2% 42.84 US$4,659,584
2026-02-03 2026-02-03 PrS Proposed sale
3.8
Terrance Coyne

Officer

Officer
135,117
42.97
US$5,805,977 		135,117 42.97 US$5,805,977
2026-02-04 2026-02-02 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
5,843 -16.2%
42.08
US$245,896 		5,843 -16.2% 42.08 US$245,896
2026-02-04 2026-02-02 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
5,843 -16.2%
42.08
US$245,896 		5,843 -16.2% 42.08 US$245,896
2026-02-04 2026-02-02 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
102,581 -26.0%
42.08
US$4,317,009 		102,581 -26.0% 42.08 US$4,317,009
2026-02-02 2026-02-02 PrS Proposed sale
3.8
Terrance Coyne

Officer

Officer
108,424
42.36
US$4,592,841 		108,424 42.36 US$4,592,841
2026-02-02 2026-01-30 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
20,000 -100.0%
41.09
US$821,810 		20,000 -100.0% 41.09 US$821,810
2026-01-26 2026-01-23 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
20,000 -50.0%
40.26
US$805,110 		20,000 -50.0% 40.26 US$805,110
2026-01-23 2026-01-20 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
3,750 -9.4%
39.35
US$147,556 		3,750 -9.4% 39.35 US$147,556
2026-01-23 2026-01-20 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
65,832 -14.3%
39.35
US$2,590,384 		65,832 -14.3% 39.35 US$2,590,384
2026-01-20 2026-01-20 PrS Proposed sale
3.8
Terrance Coyne

Officer

Officer
69,582
39.09
US$2,719,960 		69,582 39.09 US$2,719,960
2026-01-20 2026-01-16 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
20,000 -33.3%
39.52
US$790,346 		20,000 -33.3% 39.52 US$790,346
2026-01-13 2026-01-09 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
20,000 -25.0%
40.78
US$815,634 		20,000 -25.0% 40.78 US$815,634
2026-01-07 2026-01-07 PrS Proposed sale
3.8
George Lloyd

Officer

Officer
495,860
41.39
US$20,523,645 		495,860 41.39 US$20,523,645
2026-01-06 2026-01-02 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
3,750 -8.6%
38.42
US$144,059 		3,750 -8.6% 38.42 US$144,059
2026-01-06 2026-01-02 PlS Planned sale
3.8
Coyne Terrance P.

EVP & CFO

Officer
65,832 -12.5%
38.42
US$2,528,982 		65,832 -12.5% 38.42 US$2,528,982
2026-01-06 2026-01-02 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
20,000 -20.0%
38.48
US$769,650 		20,000 -20.0% 38.48 US$769,650
2026-01-02 2026-01-02 PrS Proposed sale
3.8
Terrance Coyne

Officer

Officer
69,582
38.86
US$2,703,957 		69,582 38.86 US$2,703,957
2025-12-29 2025-12-26 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
20,000 -16.7%
39.32
US$786,380 		20,000 -16.7% 39.32 US$786,380
2025-12-22 2025-12-19 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
20,000 -14.3%
38.38
US$767,582 		20,000 -14.3% 38.38 US$767,582
2025-12-19 2025-12-18 PlS Planned sale
3.8
Lloyd George W.

EVP, Investments & CLO

Officer
30,654 -100.0%
38.50
US$1,180,053 		30,654 -100.0% 38.50 US$1,180,053
2025-12-19 2025-12-17 PlS Planned sale
3.8
Lloyd George W.

EVP, Investments & CLO

Officer
79,346 -72.1%
38.57
US$3,060,280 		79,346 -72.1% 38.57 US$3,060,280
2025-12-17 2025-12-16 PlS Planned sale
3.5
Urist Marshall

EVP, Research & Investments

Officer
20,000 -12.5%
38.32
US$766,420 		20,000 -12.5% 38.32 US$766,420
2025-12-16 2025-12-16 PrS Proposed sale
Sandy Lamm LLC

Officer

Officer
160,000
38.36
US$6,137,600 		160,000 38.36 US$6,137,600
Explore more

More insider trading research around Royalty Pharma PLC

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America